AU607981B2 - Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure - Google Patents
Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure Download PDFInfo
- Publication number
- AU607981B2 AU607981B2 AU13870/88A AU1387088A AU607981B2 AU 607981 B2 AU607981 B2 AU 607981B2 AU 13870/88 A AU13870/88 A AU 13870/88A AU 1387088 A AU1387088 A AU 1387088A AU 607981 B2 AU607981 B2 AU 607981B2
- Authority
- AU
- Australia
- Prior art keywords
- prostaglandin
- composition
- eye
- mixture
- blocking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 49
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 35
- 239000000674 adrenergic antagonist Substances 0.000 title abstract description 20
- 230000009467 reduction Effects 0.000 title description 13
- 239000000203 mixture Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 25
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 22
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 21
- 230000001603 reducing effect Effects 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000000699 topical effect Effects 0.000 claims abstract description 9
- -1 -isopropyl ester Chemical class 0.000 claims description 29
- 101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 claims description 21
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical group O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 20
- 239000002876 beta blocker Substances 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 229960004834 levobunolol hydrochloride Drugs 0.000 claims description 15
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical group [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 14
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 13
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical group OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 claims description 13
- 229960005221 timolol maleate Drugs 0.000 claims description 12
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 claims description 11
- 229960004347 betaxolol hydrochloride Drugs 0.000 claims description 8
- 239000002981 blocking agent Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229960001342 dinoprost Drugs 0.000 claims description 5
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims 1
- 241000282326 Felis catus Species 0.000 description 15
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 229960004605 timolol Drugs 0.000 description 14
- 230000001077 hypotensive effect Effects 0.000 description 12
- 230000001886 ciliary effect Effects 0.000 description 11
- 210000001742 aqueous humor Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940097320 beta blocking agent Drugs 0.000 description 7
- 210000001747 pupil Anatomy 0.000 description 7
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960001416 pilocarpine Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 229960000831 levobunolol Drugs 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229940072329 betoptic Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229940098085 betagan Drugs 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001585 trabecular meshwork Anatomy 0.000 description 3
- 206010052127 Anterior chamber flare Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229960004324 betaxolol Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- FPABVZYYTCHNMK-YNRDDPJXSA-N PGF2alpha isopropyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C FPABVZYYTCHNMK-YNRDDPJXSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001710 bronchial artery Anatomy 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940034744 timoptic Drugs 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3448487A | 1987-04-03 | 1987-04-03 | |
| US034484 | 1987-04-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1387088A AU1387088A (en) | 1988-10-06 |
| AU607981B2 true AU607981B2 (en) | 1991-03-21 |
Family
ID=21876714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU13870/88A Expired AU607981B2 (en) | 1987-04-03 | 1988-03-30 | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0286903B2 (enExample) |
| JP (1) | JP2726672B2 (enExample) |
| AT (1) | ATE76750T1 (enExample) |
| AU (1) | AU607981B2 (enExample) |
| CA (1) | CA1314220C (enExample) |
| DE (1) | DE3871596T3 (enExample) |
| ES (1) | ES2042625T5 (enExample) |
| GR (2) | GR3004794T3 (enExample) |
| HU (1) | HU211835A9 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
| US5173507A (en) * | 1988-07-18 | 1992-12-22 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5198545A (en) * | 1989-11-13 | 1993-03-30 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof |
| US5055467A (en) * | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5011856A (en) * | 1990-03-12 | 1991-04-30 | Allergan, Inc. | Use of prostaglandin F3 α as an ocular hypotensive agent |
| EP0458587B1 (en) * | 1990-05-22 | 1993-07-14 | R-Tech Ueno Ltd. | Synergistic combination for ophthalmic use |
| DE69106777T2 (de) * | 1990-05-22 | 1995-05-18 | Ueno Seiyaku Oyo Kenkyujo Kk | Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination. |
| EP0458590B1 (en) * | 1990-05-22 | 1996-01-10 | R-Tech Ueno Ltd. | Treatment of ocular hypertention with a synergistic combination |
| US5238961A (en) * | 1990-06-14 | 1993-08-24 | Allergan, Inc. | Pgf 1-alcohols and their use as ocular hypotensives |
| TW210287B (enExample) * | 1991-03-01 | 1993-08-01 | Kabushikaisha Ueno Seiyaku Oyo Kenkyujo | |
| ATE207360T1 (de) * | 1992-03-19 | 2001-11-15 | R Tech Ueno Ltd | Behandlung von augenhochdruck mit betablockern und prostansäurederivaten |
| JPH06107547A (ja) * | 1992-10-01 | 1994-04-19 | Aarutetsuku Ueno:Kk | 眼科用組成物 |
| ES2105333T3 (es) * | 1992-10-13 | 1997-10-16 | Alcon Lab Inc | Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma. |
| US5574066A (en) * | 1992-10-28 | 1996-11-12 | Allergan | Intraocular pressure reducing 15-acyl prostaglandins |
| SE9402816D0 (sv) * | 1994-08-24 | 1994-08-24 | Pharmacia Ab | Method and meams for drug administration |
| US5698733A (en) * | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| JP2002501017A (ja) * | 1998-01-23 | 2002-01-15 | メルク・シャープ・エンド・ドーム・ベー・ベー | 視神経および網膜内の酸素圧を増加させるための方法 |
| KR100875908B1 (ko) * | 2001-04-19 | 2008-12-26 | 테이카 세이야쿠 가부시키가이샤 | 약제 및 약제 키트 |
| AU2007200821A1 (en) * | 2001-05-31 | 2007-03-15 | Allergan, Inc. | Hypotensive lipid and timolol compositions and methods of using same |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| TW200305424A (en) | 2002-01-29 | 2003-11-01 | Santen Pharmaceutical Co Ltd | Glaucoma-treating agent comprising bunazosin and prostaglandin |
| AU2003257588A1 (en) * | 2002-08-29 | 2004-03-19 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| CN1323719C (zh) * | 2002-11-18 | 2007-07-04 | 参天制药株式会社 | 由 Rho 激酶抑制剂和β阻断剂构成的青光眼治疗剂 |
| US7186744B2 (en) * | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| DK1905452T3 (da) | 2005-07-12 | 2013-07-01 | Kowa Co | Middel til forebyggelse eller behandling af glaukom |
| EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| US20120184552A1 (en) * | 2009-09-17 | 2012-07-19 | Senju Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| ES2911174T3 (es) | 2010-07-29 | 2022-05-18 | Allergan Inc | Soluciones de bimatoprost y timolol sin conservantes |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| TW202344254A (zh) | 2011-02-04 | 2023-11-16 | 日商興和股份有限公司 | 青光眼或高眼壓症之預防或治療用之醫藥 |
| JP6193655B2 (ja) * | 2012-07-13 | 2017-09-06 | 参天製薬株式会社 | スルホンアミド化合物の組み合わせ |
| WO2018033854A1 (en) | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
| JPWO2019124487A1 (ja) | 2017-12-21 | 2020-12-10 | 参天製薬株式会社 | オミデネパグの組合せ |
| JPWO2019124488A1 (ja) | 2017-12-21 | 2020-12-17 | 参天製薬株式会社 | セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| EP0242580A2 (en) * | 1986-03-13 | 1987-10-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
| DE3300933A1 (de) * | 1983-01-13 | 1984-07-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten |
-
1988
- 1988-03-28 DE DE3871596T patent/DE3871596T3/de not_active Expired - Lifetime
- 1988-03-28 EP EP88104999A patent/EP0286903B2/en not_active Expired - Lifetime
- 1988-03-28 AT AT88104999T patent/ATE76750T1/de not_active IP Right Cessation
- 1988-03-28 ES ES88104999T patent/ES2042625T5/es not_active Expired - Lifetime
- 1988-03-30 AU AU13870/88A patent/AU607981B2/en not_active Expired
- 1988-03-30 CA CA000562902A patent/CA1314220C/en not_active Expired - Lifetime
- 1988-04-01 JP JP63081167A patent/JP2726672B2/ja not_active Expired - Lifetime
-
1992
- 1992-06-04 GR GR920401036T patent/GR3004794T3/el unknown
-
1995
- 1995-06-28 HU HU95P/P00519P patent/HU211835A9/hu unknown
-
2000
- 2000-06-16 GR GR20000401411T patent/GR3033721T3/el not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| EP0242580A2 (en) * | 1986-03-13 | 1987-10-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
Also Published As
| Publication number | Publication date |
|---|---|
| GR3033721T3 (en) | 2000-10-31 |
| EP0286903A1 (en) | 1988-10-19 |
| ATE76750T1 (de) | 1992-06-15 |
| JPS63313728A (ja) | 1988-12-21 |
| ES2042625T3 (es) | 1993-12-16 |
| ES2042625T5 (es) | 2000-07-16 |
| JP2726672B2 (ja) | 1998-03-11 |
| DE3871596T3 (de) | 2000-09-07 |
| EP0286903B1 (en) | 1992-06-03 |
| DE3871596T2 (de) | 1993-01-21 |
| DE3871596D1 (de) | 1992-07-09 |
| EP0286903B2 (en) | 2000-03-29 |
| CA1314220C (en) | 1993-03-09 |
| AU1387088A (en) | 1988-10-06 |
| HU211835A9 (en) | 1995-12-28 |
| GR3004794T3 (enExample) | 1993-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU607981B2 (en) | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure | |
| US4952581A (en) | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | |
| EP0569046B1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| US4883819A (en) | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma | |
| Adkins et al. | Brimonidine: a review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension | |
| US6037368A (en) | 8-iso- prostaglandins for glaucoma therapy | |
| EP0777483B1 (en) | Methods and means for drug administration | |
| KR100452715B1 (ko) | 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도 | |
| CN100391461C (zh) | 降血压性脂质和噻吗洛尔组合物及其使用的方法 | |
| EP0344235B1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| EP0242580A2 (en) | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma | |
| Kemal Arici et al. | Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure | |
| Hejkal et al. | Prostaglandin analogs in the treatment of glaucoma | |
| AU609807B2 (en) | A composition for the topical treatment of glaucoma or ocular hypertension | |
| EP0979652B1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
| US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
| Scherer et al. | Effect of latanoprost on intraocular pressure following cataract extraction | |
| KR0124465B1 (ko) | 항녹내장성 안과용 조성물 | |
| KR19980701417A (ko) | 안압저하제(agent for decreasing ocular tension) | |
| US5114971A (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| US5563171A (en) | Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists | |
| Bucci | Effects of new topical β-mimetic (isoxuprine and nylidrine) and β-lytic (oxprenolol) agents on the ocular pressure in glaucomatous eyes | |
| RENGARAJ VENKATESH | COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS | |
| HK1070830B (en) | Hypotensive lipid and timolol compositions and methods of using same | |
| WO2007097205A1 (ja) | 点眼剤 |